JP2020535203A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535203A5
JP2020535203A5 JP2020518033A JP2020518033A JP2020535203A5 JP 2020535203 A5 JP2020535203 A5 JP 2020535203A5 JP 2020518033 A JP2020518033 A JP 2020518033A JP 2020518033 A JP2020518033 A JP 2020518033A JP 2020535203 A5 JP2020535203 A5 JP 2020535203A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
nucleotide sequence
sequence encoding
fragment
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020518033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535203A (ja
JP7178118B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2018/011529 external-priority patent/WO2019066556A1/ko
Publication of JP2020535203A publication Critical patent/JP2020535203A/ja
Publication of JP2020535203A5 publication Critical patent/JP2020535203A5/ja
Application granted granted Critical
Publication of JP7178118B2 publication Critical patent/JP7178118B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020518033A 2017-09-29 2018-09-28 不整脈を予防または治療するための医薬組成物 Active JP7178118B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170127550 2017-09-29
KR10-2017-0127550 2017-09-29
PCT/KR2018/011529 WO2019066556A1 (ko) 2017-09-29 2018-09-28 심장 부정맥의 예방 또는 치료용 약학적 조성물

Publications (3)

Publication Number Publication Date
JP2020535203A JP2020535203A (ja) 2020-12-03
JP2020535203A5 true JP2020535203A5 (enExample) 2021-11-04
JP7178118B2 JP7178118B2 (ja) 2022-11-25

Family

ID=65902177

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020518033A Active JP7178118B2 (ja) 2017-09-29 2018-09-28 不整脈を予防または治療するための医薬組成物

Country Status (6)

Country Link
US (1) US11761019B2 (enExample)
EP (1) EP3689363A4 (enExample)
JP (1) JP7178118B2 (enExample)
KR (2) KR20190038425A (enExample)
CN (1) CN111542334B (enExample)
WO (1) WO2019066556A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7240749B2 (ja) * 2017-09-29 2023-03-16 ベスファジェン・インコーポレイテッド 心不全の予防または治療のための医薬組成物
KR20240173703A (ko) * 2023-06-05 2024-12-13 (주)벳바젠 포스포람반의 단백질 포스파타아제 1-매개 탈인산화 억제용 데코이 펩타이드를 암호화하는 뉴클레오타이드 및 ccn5 단백질 또는 이의 단편을 암호화하는 뉴클레오타이드를 포함하는 유전자 컨스트럭트 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US20090239940A1 (en) 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
EP1382347A1 (en) * 2002-07-17 2004-01-21 UNIVERSITE PARIS 7 - Denis DIDEROT Use of CCN protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
WO2006007444A2 (en) 2004-06-16 2006-01-19 The Trustees Of Columbia University In The City Of New York CaMKII/CALCIUM CHANNEL BINDING-RELATED COMPOSITIONS AND METHODS
KR101187814B1 (ko) * 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
EP3004343B1 (en) * 2013-06-07 2018-10-10 The Regents of The University of California Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function
CN108778311A (zh) * 2015-11-13 2018-11-09 贝特基因 用于治疗心脏纤维化的药物组合物

Similar Documents

Publication Publication Date Title
JP2020518268A5 (enExample)
ES2387082T3 (es) Uso de OSTEOPONTINA para el tratamiento y/o prevención de enfermedades neurológicas
JP2020073536A5 (enExample)
JP2011525363A5 (enExample)
JP2020519292A5 (enExample)
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
KR20180102172A (ko) 다논병 및 다른 자가포식 장애의 치료 방법
JP2006502702A5 (enExample)
JP2017523239A5 (enExample)
JP2018537089A5 (enExample)
JP2020535203A5 (enExample)
JP2004501650A5 (enExample)
KR20230084542A (ko) 플라코필린 2 유전자 치료 방법 및 조성물
RU2019126509A (ru) Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
JP2018509154A5 (enExample)
Guo et al. Molecular cloning and characterization of a novel bovine IFN-ε
JP2003189887A5 (enExample)
JP2020536519A5 (enExample)
RU2639582C2 (ru) Композиция для предупреждения или лечения бокового амиотрофического склероза с использованием двух или более изоформ фактора роста гепатоцитов
CN107073078B (zh) 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物
US20050113291A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
US20150118187A1 (en) Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
RU2020114946A (ru) Фармацевтическая композиция для профилактики или лечения аритмии сердца
O'Neill et al. Comparison of SNCG and NEFH promoter–driven expression of human SIRT1 expression in a mouse model of glaucoma
ES3006614T3 (en) Relaxin receptor 1 for use in treatment and prevention of heart failure